Characteristics Predicting Tuberculosis Risk under Tumor Necrosis Factor-α Inhibitors: Report from a Large Multicenter Cohort with High Background Prevalence

Abstract

Our results suggest that TB is an important complication of anti-TNF therapies in Turkey. TB chemoprophylaxis less than 9 months and the use of IFX therapy were independent risk factors for TB development.

Peritoneal tuberculosis in the setting of ustekinumab treatment for psoriasis

“…There is an increased risk of reactivation of TB, particularly in extrapulmonary sites, in patients treated with TNF-α inhibitors 11 . To our knowledge, this is the first case of peritoneal TB reported in a patient receiving ustekinumab treatment.…”

Role of Th1/Th2 cytokines in the diagnosis and prognostic evaluation of ankylosing spondylitis

“…Patients with AS have strong sex preference, as it occurs frequently in young males in the age group of 20-30 years (Lindström et al, 2016b;Zou et al, 2016). Although AS has an insidious onset and slow progression, no effective treatment has been found, which severely affects the efficacy of treatment (Fischer et al, 2015;Kisacik et al, 2016a). AS can affect the tissues of the spine and major joints of the body, which elicit an inflammatory response (Colombo et al, 2015;Hoxha et al, 2016).…”

Recombinant human lactoferrin modulates human PBMC derived macrophage responses to BCG and LPS

“…The increase in CD16 + monocytes is correlated with severity of active TB disease [26]. CD16 + monocytes isolated from TB patients with poorer clinical outcomes are less responsive to stimulation with MTB antigens or LPS, producing significantly less TNF-α [27], a cytokine whose decrease has been linked to TB disease activation [28,29]. This increase in CD16 + monocytes could be a direct result of MTB infection altering the CD14 + monocytes.…”